BioCentury | Mar 5, 2007
Emerging Company Profile

ApopLogic: Finding cell death drivers

...healthy cells. He believes that side effects of previous bradykinin antagonists, such as Bradycor from Cortech Inc....
BioCentury | Jan 16, 2006
Strategy

Emigrating in the private space

...the GABA A and acetylcholine receptors. Although clinical testing of a bradykinin inhibitor, Bradycor from Cortech Inc....
BioCentury | Jun 27, 2005
Product Development

Back to bradykinin

...a small pharmacokinetics study that was run in parallel. SmithKline returned Bradycor rights to partner Cortech Inc....
BioCentury | Oct 14, 2002
Clinical News

ONO-6818: Clinical

...to collect and analyze data, and has not determined the future development of the compound. Cortech Inc....
BioCentury | Aug 19, 2002
Company News

Cortech, Ono autoimmune/inflammation news

...non-oral uses, CRTQ said the panel agreed that the companies must share non-exclusive rights worldwide. Cortech Inc....
BioCentury | Aug 27, 2001
Company News

RxKinetix management update

...Janice Troha as VP of clinical development and regulatory affairs, formerly VP of development at Cortech Inc. WIR...
BioCentury | Jul 3, 2000
Tools & Techniques

Lilly's sepsis success

...CHIR, Emeryville, Calif.) and partner Bayer (DAX:BAYG, Leverkusen, Germany); and Bradycor bradykinin inhibitor developed by Cortech Inc....
BioCentury | Jul 3, 2000
Clinical News

UT-77: Discontinued Phase II development

...Phase II and preclinical data. The company said that the compound, which was in-licensed from Cortech Inc....
BioCentury | Jun 27, 2000
Top Story

UTHR discontinues UT-77

...II and preclinical data. CFO Fred Hadeed said that the compound, which was in-licensed from Cortech...
BioCentury | Apr 3, 2000
Finance

Janus denies any special insight

...in the offing: a "light-hearted" book on the industry in collaboration with David Crossen, former Cortech...
Items per page:
1 - 10 of 90
BioCentury | Mar 5, 2007
Emerging Company Profile

ApopLogic: Finding cell death drivers

...healthy cells. He believes that side effects of previous bradykinin antagonists, such as Bradycor from Cortech Inc....
BioCentury | Jan 16, 2006
Strategy

Emigrating in the private space

...the GABA A and acetylcholine receptors. Although clinical testing of a bradykinin inhibitor, Bradycor from Cortech Inc....
BioCentury | Jun 27, 2005
Product Development

Back to bradykinin

...a small pharmacokinetics study that was run in parallel. SmithKline returned Bradycor rights to partner Cortech Inc....
BioCentury | Oct 14, 2002
Clinical News

ONO-6818: Clinical

...to collect and analyze data, and has not determined the future development of the compound. Cortech Inc....
BioCentury | Aug 19, 2002
Company News

Cortech, Ono autoimmune/inflammation news

...non-oral uses, CRTQ said the panel agreed that the companies must share non-exclusive rights worldwide. Cortech Inc....
BioCentury | Aug 27, 2001
Company News

RxKinetix management update

...Janice Troha as VP of clinical development and regulatory affairs, formerly VP of development at Cortech Inc. WIR...
BioCentury | Jul 3, 2000
Tools & Techniques

Lilly's sepsis success

...CHIR, Emeryville, Calif.) and partner Bayer (DAX:BAYG, Leverkusen, Germany); and Bradycor bradykinin inhibitor developed by Cortech Inc....
BioCentury | Jul 3, 2000
Clinical News

UT-77: Discontinued Phase II development

...Phase II and preclinical data. The company said that the compound, which was in-licensed from Cortech Inc....
BioCentury | Jun 27, 2000
Top Story

UTHR discontinues UT-77

...II and preclinical data. CFO Fred Hadeed said that the compound, which was in-licensed from Cortech...
BioCentury | Apr 3, 2000
Finance

Janus denies any special insight

...in the offing: a "light-hearted" book on the industry in collaboration with David Crossen, former Cortech...
Items per page:
1 - 10 of 90